[Reduction in 28 days and 6 months of acute myocardial infarction mortality from 1995 to 2005. Data from PRIAMHO I, II and MASCARA registries]

Rev Esp Cardiol. 2011 Nov;64(11):972-80. doi: 10.1016/j.recesp.2011.05.011. Epub 2011 Jul 30.
[Article in Spanish]

Abstract

Introduction and objectives: To determine whether mortality from acute myocardial infarction has reduced in Spain and the possibly related therapeutic factors.

Methods: Nine thousand, nine hundred and forty-nine patients with ST-segment elevation myocardial infarction admitted to the Coronary Care Unit were identified from PRIAMHO I, II and MASCARA registries performed in 1995, 2000 and 2005, with a 6 month follow-up.

Results: From 1995 to 2005 patients were increasingly more likely to have hypertension, hyperlipidemia and anterior infarction, but age of onset and the proportion of females did not increase. Twenty-eight-day mortality rates were 12.6%, 12.3% and 6% in 1995, 2000 and 2005 respectively, and 15.3%, 14.6% and 9.4% at 6 months (both P-trend <.001). Multivariate analysis was performed and the adjusted odds ratio for 28-day mortality for an infarction occuring in 2005 (compared with 1995) was 0.62 (95% confidence interval: 0.44-0.88) whereas the adjusted hazard ratio for mortality at 6 months was 0.40 (95% confidence interval: 0.24-0.67). Other variables independently associated with lower mortality at 28 days were: reperfusion therapy, and the use of anti-thrombotic treatment, beta-blockers and angiotensin-converting enzyme inhibitors. The 28-day-6-month period had an independent protective effect on the following therapies: coronary reperfusion, and prescription of antiplatelet agents, beta-blockers and lipid lowering drugs upon discharge.

Conclusions: Twenty-eight-day and six-month mortality rates fell among patients with ST-elevation myocardial infarction in Spain from 1995 to 2005. The possibly related therapeutic factors were the following: more frequent reperfusion therapy and increased use of anti-thrombotic drugs, beta-blockers, angiotensin-converting enzyme inhibitors and lipid lowering drugs.

Publication types

  • English Abstract

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Critical Care
  • Disease Management
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Hyperlipidemias / complications
  • Hyperlipidemias / epidemiology
  • Hypertension / complications
  • Hypertension / epidemiology
  • Hypolipidemic Agents / therapeutic use
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Infarction / mortality*
  • Myocardial Infarction / therapy*
  • Odds Ratio
  • Platelet Aggregation Inhibitors / therapeutic use
  • Proportional Hazards Models
  • Registries
  • Sex Factors
  • Spain / epidemiology

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Fibrinolytic Agents
  • Hypolipidemic Agents
  • Platelet Aggregation Inhibitors